46 Woodstock Road,
Oxford, OX2 6HT
JAN 29, 2025
Oxford, UK and Los Angeles, USA – 29 January 2025 – Oxford Science Enterprises (OSE) and Cedars-Sinai Intellectual Property Company today announce a strategic partnership to drive growth and expand opportunities for health-tech start-ups in both the US and UK.
The collaboration will include the ability to co-build and co-invest in new ventures emerging from Oxford. Together, the two organisations aim to foster the growth of innovative health-tech start-ups, expand U.S. and U.K. market reach, and explore future potential alliances on both sides of the Atlantic.
As the first step in this partnership, OSE and Cedars-Sinai Intellectual Property Company have co-invested $2 million in Neu Health, a University of Oxford spinout. The London-based company offers a digital smartphone-based neurology care platform designed to improve outcomes for patients with Parkinson’s disease and dementia. Neu Health previously participated in Cedars-Sinai’s 10th Accelerator program.
Neu Health’s platform, developed from over a decade of Oxford research, combines a patient app with a care team dashboard. Using AI, it translates patient symptoms and cognitive data into clear, actionable insights for clinicians. In the UK, Neu Health is gaining rapid traction, showing a clear impact on patient satisfaction and care quality. The company will now pilot its platform at Cedars-Sinai, with the first 150 neurology patients expected to begin using the app soon as part of a six-month program.
Shlomo Melmed, MB, ChB, Executive Vice President of Medicine and Health Sciences and Dean of the Medical Faculty at Cedars-Sinai, said:
“The research produced at Oxford is of the highest calibre. An ongoing relationship with Oxford Science Enterprises will serve our patients and also strengthen the academic and clinical missions of Cedars-Sinai.”
Heather Roxborough, Senior Partner and Head of Health Tech at OSE, said:
“We are excited to strengthen our relationship with Cedars-Sinai, a leading U.S. health system, given our shared commitment to commercialising world-leading research and building innovative businesses. This partnership plays a critical role in accelerating US market entry for our companies by providing access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies live in the US market.”
James D. Laur, JD, Chief Executive of Cedars-Sinai Intellectual Property Company, said:
“Investing in the research and technology coming out of Oxford through our partnership with Oxford Science Enterprises is the beginning of what we hope will become a long and fruitful relationship. Together, we can work on furthering Cedars-Sinai’s mission of providing patients around the world the best care possible.